KRAS and lung carcinoma: These results uncover a novel homeostatic mechanism of metabolic stress mediated by NOP56 and validate an unexpected synthetic lethality by targeting NOP56 and mTOR that aggregate a metabolic liability in KRAS-mutant lung cancer (Fig. 5C).